Global Systemic Scleroderma Treatment Market By Drug Class (Immunosuppressant, Phosphodiesterase 5 Inhibitors (PHA), Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, and Others), By Distribution Channel (Offline Pharmacies, Online Pharmacies), By Disease Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, and Systemic Sclerosis Sine Scleroderma), By Route of Administration (Oral and Parenteral), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Systemic sclerosis treatment, which is a form of medicine used to treat the disease, may be beneficial to patients. Immunosuppressants and phosphodiesterase-V inhibitors, when combined with other drugs, can help to reduce the thickness of the skin caused by scleroderma. The global systemic scleroderma treatment market is divided into three segments based on drug class, distribution channel, diseases type, route of administration and geography. Immunosuppressants, phosphodiesterase inhibitors (PDE), endothelin receptor antagonists (ERA), prostacyclin analogues (PGI), and calcium channel blockers are only a few of the drugs available. An upsurge in the prevalence of scleroderma along with rising approvals of novel medicines, increase in collaborations, acquisitions, and partnerships among large rivals, are the market's key developments. The systemic scleroderma treatment market is predicted to rise as a result of these key breakthroughs.
One of the key factors driving the growth and demand for scleroderma (systemic sclerosis) treatments is increased government activities and programmes targeted at boosting knowledge of the ailment and treatment choices available. Another element that is fuelling the growth and demand for these treatments is the significant increase in government activities and programmes. Aside from that, continued technological advancements are expected to contribute to an increase in the global systemic scleroderma treatment market from 2022 to 2030. The market is growing due to an increase in the incidence and screening rates of sclerosing spondylitis, as well as an increase in disposable income. Similarly, there will be a major growth in the general public's understanding of preventive healthcare over the projection period, which would aid in the market growth.
During the projection period of 2022 to 2030, increased investment in research and development for the expansion of therapy for systemic sclerosis would accelerate the systemic scleroderma treatment market and generate significant growth potential. Despite this, the lack of a specific treatment for scleroderma (systemic sclerosis) and the availability of only treatment alternatives for the disease's symptoms would limit the market's growth. Furthermore, the diagnosis and cause of the disease remains unknown, making medicine selection for symptom relief even more challenging for doctors, as each instance of scleroderma is distinct, posing a danger to the market's growth.
After being identified in Wuhan, China, in December 2019, the World Health Organization (WHO) designated SARS-CoV-2 (severe acute respiratory syndrome coronavirus) a worldwide pandemic. This SARS-CoV-2 infection was classified as a new Coronavirus by the World Health Organization (WHO) (COVID-19). COVID-19 has had a substantial detrimental influence on the healthcare business. It has wreaked havoc in the entire supply chain, from raw materials to manufacturing and delivery. The discovery of a link between COVID-19 and systemic scleroderma is projected to boost the systemic scleroderma treatment market overall growth during the course of the pandemic. The global systemic scleroderma treatment is estimated to reach US$ 1,520.1 Mn in 2021, indicating a compound annual growth rate (CAGR) of 4.2 percent (2022-2030).
Global Systemic Scleroderma Treatment Market Revenue & Forecast, (US$ Million), 2015 – 2030
Drug Class Outlook
In 2021, immunosuppressors were the most profitable segment of the systemic scleroderma treatment market, accounting for 64.2 percent of total revenue. Because there is no cure for this disease at present time, a wide range of pharmacological classes are utilised to alleviate the symptoms. Immunosuppressants are most widely prescribed and they include various biologics from well-known corporations such as Roche. Many pipeline treatments for systemic scleroderma are focusing on biologics and small-molecule immunosuppressors, which are two developing groups.
Distribution Channel Outlook
Online and Offline pharmacies are the types of distribution channels in which the global systemic scleroderma treatment market has been bifurcated. The majority of the market was dominated by offline pharmacies in 2021.
Region Outlook
In 2021, North America dominated the global systemic scleroderma treatment market, contributing for 42.9 percent of total revenue. In developed countries, growing number of biologics are being used, resulting in a larger regional market. The key revenue generator is the availability of recently developed immunosuppressants, together with a favourable reimbursement scenario.
Competitive Environment
There is a lot of possibility for development and a lot of unmet medical need in the systemic scleroderma treatment market. Pharmaceutical businesses are expanding their global market share through mergers and acquisitions, as well as via joint partnerships. This is the fundamental explanation for the widespread use of immunosuppressants in the treatment of PAH and ILD caused by scleroderma. Due to the higher penetration of this class of medications and their improved efficacy over existing options such as cyclophosphamide, methotrexate, and mycophenolate mofetil, this class of treatments will continue to be utilised until cures are discovered in clinical trials.
List of Key Players in the Global Systemic Scleroderma Treatment Market
- Amgen Inc.
- Argentis Pharmaceuticals, LLC
- Bayer AG
- Biogen
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Celgene Corporation
- Corbus Pharmaceuticals Holdings, Inc
- Eli Lilly and Company
- GlaxoSmithKline plc
- Hoffmann La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Mylan N.V.
- Novartis AG
- Ono pharmaceutical co. Ltd.
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- United Therapeutics
- Other Market Participants
Global Systemic Scleroderma Treatment Market
By Drug Class
- Immunosuppressant
- Phosphodiesterase 5 Inhibitors (PHA)
- Endothelin Receptor Antagonists
- Prostacyclin Analogues
- Calcium Channel Blockers
- Others
By Distribution Channel
- Offline
- Online
By Disease Type
- Limited Systemic Sclerosis
- Diffused Systemic Sclerosis
- Systemic Sclerosis Sine Scleroderma
By Route of Administration
- Oral
- Parenteral
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Systemic Scleroderma Treatment Market
6.
Market
Synopsis: Systemic Scleroderma Treatment
Market
7.
Systemic
Scleroderma Treatment Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Systemic Scleroderma Treatment
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Systemic Scleroderma Treatment Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Systemic Scleroderma
Treatment Market
8.
Global
Systemic Scleroderma Treatment Market Analysis and Forecasts, 2022 - 2030
8.1. Overview
8.1.1. Global Systemic Scleroderma Treatment Market
Revenue (US$ Mn)
8.2. Global Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Drug Class
8.2.1. Immunosuppressant
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. Phosphodiesterase 5 Inhibitors (PHA)
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.2.3. Endothelin Receptor Antagonists
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 - 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 - 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 - 2030
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 - 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 - 2030
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 - 2030
8.2.4. Prostacyclin Analogues
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 - 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 - 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 - 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 - 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 - 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 - 2030
8.2.5. Calcium Channel Blockers
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 - 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 - 2030
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 - 2030
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 - 2030
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 - 2030
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 - 2030
8.2.6. Others
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.6.3.
Market
Forecast, 2022 - 2030
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2021
8.2.6.5.1.2. Market Forecast, 2022 - 2030
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2021
8.2.6.5.2.2. Market Forecast, 2022 - 2030
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2021
8.2.6.5.3.2. Market Forecast, 2022 - 2030
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2021
8.2.6.5.4.2. Market Forecast, 2022 - 2030
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2021
8.2.6.5.5.2. Market Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Drug Class
9.
Global
Systemic Scleroderma Treatment Market Analysis and Forecasts, 2022 - 2030
9.1. Overview
9.2. Global Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
9.2.1. Offline
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2. Online
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Distribution Channel
10. Global Systemic Scleroderma Treatment Market
Analysis and Forecasts, 2022 - 2030
10.1. Overview
10.2. Global Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Disease Type
10.2.1. Limited Systemic Sclerosis
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 - 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Diffused Systemic Sclerosis
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 - 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3.
Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. Systemic Sclerosis Sine Scleroderma
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.3.3.
Market
Forecast, 2022 - 2030
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Disease Type
11. Global Systemic Scleroderma Treatment Market
Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.2. Global Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
11.2.1. Oral
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 - 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 - 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 - 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 - 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 - 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 - 2030
11.2.2. Parenteral
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 - 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 - 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 - 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 - 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 - 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 - 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Route of Administration
12. North America Systemic Scleroderma Treatment
Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. North America Systemic Scleroderma Treatment
Market Revenue (US$ Mn)
12.2. North America Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Drug Class
12.2.1. Immunosuppressant
12.2.2. Phosphodiesterase 5 Inhibitors (PHA)
12.2.3. Endothelin Receptor Antagonists
12.2.4. Prostacyclin Analogues
12.2.5. Calcium Channel Blockers
12.2.6. Others
12.3. North America Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.3.1. Offline
12.3.2. Online
12.4. North America Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Disease Type
12.4.1. Limited Systemic Sclerosis
12.4.2. Diffused Systemic Sclerosis
12.4.3. Systemic Sclerosis Sine Scleroderma
12.5. North America Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.5.1. Oral
12.5.2. Parenteral
12.6. North America Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
12.6.1.1.1.
Immunosuppressant
12.6.1.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
12.6.1.1.3.
Endothelin
Receptor Antagonists
12.6.1.1.4.
Prostacyclin
Analogues
12.6.1.1.5.
Calcium
Channel Blockers
12.6.1.1.6.
Others
12.6.1.2.
U.S
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.6.1.2.1.
Offline
12.6.1.2.2.
Online
12.6.1.3.
U.S
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
12.6.1.3.1.
Limited
Systemic Sclerosis
12.6.1.3.2.
Diffused
Systemic Sclerosis
12.6.1.3.3.
Systemic
Sclerosis Sine Scleroderma
12.6.1.4.
U.S
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
12.6.1.4.1.
Oral
12.6.1.4.2.
Parenteral
12.6.2. Canada
12.6.2.1.
Canada
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
12.6.2.1.1.
Immunosuppressant
12.6.2.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
12.6.2.1.3.
Endothelin
Receptor Antagonists
12.6.2.1.4.
Prostacyclin
Analogues
12.6.2.1.5.
Calcium
Channel Blockers
12.6.2.1.6.
Others
12.6.2.2.
Canada
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.6.2.2.1.
Offline
12.6.2.2.2.
Online
12.6.2.3.
Canada
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
12.6.2.3.1.
Limited
Systemic Sclerosis
12.6.2.3.2.
Diffused
Systemic Sclerosis
12.6.2.3.3.
Systemic
Sclerosis Sine Scleroderma
12.6.2.4.
Canada
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
12.6.2.4.1.
Oral
12.6.2.4.2.
Parenteral
12.6.3. Mexico
12.6.3.1.
Mexico
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
12.6.3.1.1.
Immunosuppressant
12.6.3.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
12.6.3.1.3.
Endothelin
Receptor Antagonists
12.6.3.1.4.
Prostacyclin
Analogues
12.6.3.1.5.
Calcium
Channel Blockers
12.6.3.1.6.
Others
12.6.3.2.
Mexico
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.6.3.2.1.
Offline
12.6.3.2.2.
Online
12.6.3.3.
Mexico
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
12.6.3.3.1.
Limited
Systemic Sclerosis
12.6.3.3.2.
Diffused
Systemic Sclerosis
12.6.3.3.3.
Systemic
Sclerosis Sine Scleroderma
12.6.3.4.
Mexico
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
12.6.3.4.1.
Oral
12.6.3.4.2.
Parenteral
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Drug Class
12.6.4.1.1.
Immunosuppressant
12.6.4.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
12.6.4.1.3.
Endothelin
Receptor Antagonists
12.6.4.1.4.
Prostacyclin
Analogues
12.6.4.1.5.
Calcium
Channel Blockers
12.6.4.1.6.
Others
12.6.4.2.
Rest of
North America Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.6.4.2.1.
Offline
12.6.4.2.2.
Online
12.6.4.3.
Rest of
North America Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Disease Type
12.6.4.3.1.
Limited
Systemic Sclerosis
12.6.4.3.2.
Diffused
Systemic Sclerosis
12.6.4.3.3.
Systemic
Sclerosis Sine Scleroderma
12.6.4.4.
Rest of
North America Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
12.6.4.4.1.
Oral
12.6.4.4.2.
Parenteral
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Drug Class
12.7.3. By Distribution Channel
12.7.4. By Disease Type
12.7.5. By Route of Administration
13. Europe Systemic Scleroderma Treatment Market
Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Europe Systemic Scleroderma Treatment Market
Revenue (US$ Mn)
13.2. Europe Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Drug Class
13.2.1. Immunosuppressant
13.2.2. Phosphodiesterase 5 Inhibitors (PHA)
13.2.3. Endothelin Receptor Antagonists
13.2.4. Prostacyclin Analogues
13.2.5. Calcium Channel Blockers
13.2.6. Others
13.3. Europe Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.3.1. Offline
13.3.2. Online
13.4. Europe Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Disease Type
13.4.1. Limited Systemic Sclerosis
13.4.2. Diffused Systemic Sclerosis
13.4.3. Systemic Sclerosis Sine Scleroderma
13.5. Europe Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.5.1. Oral
13.5.2. Parenteral
13.6. Europe Systemic Scleroderma Treatment Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1.
France
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
13.6.1.1.1.
Immunosuppressant
13.6.1.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
13.6.1.1.3.
Endothelin
Receptor Antagonists
13.6.1.1.4.
Prostacyclin
Analogues
13.6.1.1.5.
Calcium
Channel Blockers
13.6.1.1.6.
Others
13.6.1.2.
France
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.1.2.1.
Offline
13.6.1.2.2.
Online
13.6.1.3.
France
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
13.6.1.3.1.
Limited
Systemic Sclerosis
13.6.1.3.2.
Diffused
Systemic Sclerosis
13.6.1.3.3.
Systemic
Sclerosis Sine Scleroderma
13.6.1.4.
France Systemic
Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.6.1.4.1.
Oral
13.6.1.4.2.
Parenteral
13.6.2. The UK
13.6.2.1.
The UK
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
13.6.2.1.1.
Immunosuppressant
13.6.2.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
13.6.2.1.3.
Endothelin
Receptor Antagonists
13.6.2.1.4.
Prostacyclin
Analogues
13.6.2.1.5.
Calcium
Channel Blockers
13.6.2.1.6.
Others
13.6.2.2.
The UK
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.2.2.1.
Offline
13.6.2.2.2.
Online
13.6.2.3.
The UK
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
13.6.2.3.1.
Limited
Systemic Sclerosis
13.6.2.3.2.
Diffused
Systemic Sclerosis
13.6.2.3.3.
Systemic
Sclerosis Sine Scleroderma
13.6.2.4.
The UK
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
13.6.2.4.1.
Oral
13.6.2.4.2.
Parenteral
13.6.3. Spain
13.6.3.1.
Spain
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
13.6.3.1.1.
Immunosuppressant
13.6.3.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
13.6.3.1.3.
Endothelin
Receptor Antagonists
13.6.3.1.4.
Prostacyclin
Analogues
13.6.3.1.5.
Calcium
Channel Blockers
13.6.3.1.6.
Others
13.6.3.2.
Spain
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.3.2.1.
Offline
13.6.3.2.2.
Online
13.6.3.3.
Spain
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
13.6.3.3.1.
Limited
Systemic Sclerosis
13.6.3.3.2.
Diffused
Systemic Sclerosis
13.6.3.3.3.
Systemic
Sclerosis Sine Scleroderma
13.6.3.4.
Spain
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
13.6.3.4.1.
Oral
13.6.3.4.2.
Parenteral
13.6.4. Germany
13.6.4.1.
Germany
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
13.6.4.1.1.
Immunosuppressant
13.6.4.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
13.6.4.1.3.
Endothelin
Receptor Antagonists
13.6.4.1.4.
Prostacyclin
Analogues
13.6.4.1.5.
Calcium
Channel Blockers
13.6.4.1.6.
Others
13.6.4.2.
Germany
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.4.2.1.
Offline
13.6.4.2.2.
Online
13.6.4.3.
Germany
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
13.6.4.3.1.
Limited
Systemic Sclerosis
13.6.4.3.2.
Diffused
Systemic Sclerosis
13.6.4.3.3.
Systemic
Sclerosis Sine Scleroderma
13.6.4.4.
Germany
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
13.6.4.4.1.
Oral
13.6.4.4.2.
Parenteral
13.6.5. Italy
13.6.5.1.
Italy
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
13.6.5.1.1.
Immunosuppressant
13.6.5.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
13.6.5.1.3.
Endothelin
Receptor Antagonists
13.6.5.1.4.
Prostacyclin
Analogues
13.6.5.1.5.
Calcium
Channel Blockers
13.6.5.1.6.
Others
13.6.5.2.
Italy
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.5.2.1.
Offline
13.6.5.2.2.
Online
13.6.5.3.
Italy
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
13.6.5.3.1.
Limited
Systemic Sclerosis
13.6.5.3.2.
Diffused
Systemic Sclerosis
13.6.5.3.3.
Systemic
Sclerosis Sine Scleroderma
13.6.5.4.
Italy
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
13.6.5.4.1.
Oral
13.6.5.4.2.
Parenteral
13.6.6. Nordic Countries
13.6.6.1.
Nordic
Countries Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts,
By Drug Class
13.6.6.1.1.
Immunosuppressant
13.6.6.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
13.6.6.1.3.
Endothelin
Receptor Antagonists
13.6.6.1.4.
Prostacyclin
Analogues
13.6.6.1.5.
Calcium
Channel Blockers
13.6.6.1.6.
Others
13.6.6.2.
Nordic
Countries Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
13.6.6.2.1.
Offline
13.6.6.2.2.
Online
13.6.6.3.
Nordic
Countries Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts,
By Disease Type
13.6.6.3.1.
Limited
Systemic Sclerosis
13.6.6.3.2.
Diffused
Systemic Sclerosis
13.6.6.3.3.
Systemic
Sclerosis Sine Scleroderma
13.6.6.4.
Nordic
Countries Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
13.6.6.4.1.
Oral
13.6.6.4.2.
Parenteral
13.6.6.5.
Nordic
Countries Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts,
By Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Drug Class
13.6.7.1.1.
Immunosuppressant
13.6.7.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
13.6.7.1.3.
Endothelin
Receptor Antagonists
13.6.7.1.4.
Prostacyclin
Analogues
13.6.7.1.5.
Calcium
Channel Blockers
13.6.7.1.6.
Others
13.6.7.2.
Benelux
Union Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.7.2.1.
Offline
13.6.7.2.2.
Online
13.6.7.3.
Benelux
Union Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
13.6.7.3.1.
Limited
Systemic Sclerosis
13.6.7.3.2.
Diffused
Systemic Sclerosis
13.6.7.3.3.
Systemic
Sclerosis Sine Scleroderma
13.6.7.4.
Benelux
Union Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
13.6.7.4.1.
Oral
13.6.7.4.2.
Parenteral
13.6.7.5.
Benelux Union
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Drug Class
13.6.8.1.1.
Immunosuppressant
13.6.8.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
13.6.8.1.3.
Endothelin
Receptor Antagonists
13.6.8.1.4.
Prostacyclin
Analogues
13.6.8.1.5.
Calcium
Channel Blockers
13.6.8.1.6.
Others
13.6.8.2.
Rest of
Europe Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.8.2.1.
Offline
13.6.8.2.2.
Online
13.6.8.3.
Rest of Europe
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
13.6.8.3.1.
Limited
Systemic Sclerosis
13.6.8.3.2.
Diffused
Systemic Sclerosis
13.6.8.3.3.
Systemic
Sclerosis Sine Scleroderma
13.6.8.4.
Rest of
Europe Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
13.6.8.4.1.
Oral
13.6.8.4.2.
Parenteral
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Drug Class
13.7.3. By Distribution Channel
13.7.4. By Disease Type
13.7.5. By Route of Administration
14. Asia Pacific Systemic Scleroderma Treatment
Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Asia Pacific Systemic Scleroderma Treatment
Market Revenue (US$ Mn)
14.2. Asia Pacific Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.2.1. Immunosuppressant
14.2.2. Phosphodiesterase 5 Inhibitors (PHA)
14.2.3. Endothelin Receptor Antagonists
14.2.4. Prostacyclin Analogues
14.2.5. Calcium Channel Blockers
14.2.6. Others
14.3. Asia Pacific Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.3.1. Offline
14.3.2. Online
14.4. Asia Pacific Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Disease Type
14.4.1. Limited Systemic Sclerosis
14.4.2. Diffused Systemic Sclerosis
14.4.3. Systemic Sclerosis Sine Scleroderma
14.5. Asia Pacific Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.5.1. Oral
14.5.2. Parenteral
14.6. Asia Pacific Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.6.1.1.1.
Immunosuppressant
14.6.1.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
14.6.1.1.3.
Endothelin
Receptor Antagonists
14.6.1.1.4.
Prostacyclin
Analogues
14.6.1.1.5.
Calcium
Channel Blockers
14.6.1.1.6.
Others
14.6.1.2.
China
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.1.2.1.
Offline
14.6.1.2.2.
Online
14.6.1.3.
China
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
14.6.1.3.1.
Limited
Systemic Sclerosis
14.6.1.3.2.
Diffused
Systemic Sclerosis
14.6.1.3.3.
Systemic
Sclerosis Sine Scleroderma
14.6.1.4.
China
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.6.1.4.1.
Oral
14.6.1.4.2.
Parenteral
14.6.2. Japan
14.6.2.1.
Japan
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.6.2.1.1.
Immunosuppressant
14.6.2.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
14.6.2.1.3.
Endothelin
Receptor Antagonists
14.6.2.1.4.
Prostacyclin
Analogues
14.6.2.1.5.
Calcium
Channel Blockers
14.6.2.1.6.
Others
14.6.2.2.
Japan
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.2.2.1.
Offline
14.6.2.2.2.
Online
14.6.2.3.
Japan
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
14.6.2.3.1.
Limited
Systemic Sclerosis
14.6.2.3.2.
Diffused
Systemic Sclerosis
14.6.2.3.3.
Systemic
Sclerosis Sine Scleroderma
14.6.2.4.
Japan
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.6.2.4.1.
Oral
14.6.2.4.2.
Parenteral
14.6.3. India
14.6.3.1.
India
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.6.3.1.1.
Immunosuppressant
14.6.3.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
14.6.3.1.3.
Endothelin
Receptor Antagonists
14.6.3.1.4.
Prostacyclin
Analogues
14.6.3.1.5.
Calcium
Channel Blockers
14.6.3.1.6.
Others
14.6.3.2.
India
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.3.2.1.
Offline
14.6.3.2.2.
Online
14.6.3.3.
India
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
14.6.3.3.1.
Limited
Systemic Sclerosis
14.6.3.3.2.
Diffused
Systemic Sclerosis
14.6.3.3.3.
Systemic
Sclerosis Sine Scleroderma
14.6.3.4.
India
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.6.3.4.1.
Oral
14.6.3.4.2.
Parenteral
14.6.4. New Zealand
14.6.4.1.
New
Zealand Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts,
By Drug Class
14.6.4.1.1.
Immunosuppressant
14.6.4.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
14.6.4.1.3.
Endothelin
Receptor Antagonists
14.6.4.1.4.
Prostacyclin
Analogues
14.6.4.1.5.
Calcium
Channel Blockers
14.6.4.1.6.
Others
14.6.4.2.
New
Zealand Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
14.6.4.2.1.
Offline
14.6.4.2.2.
Online
14.6.4.3.
New
Zealand Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts,
By Disease Type
14.6.4.3.1.
Limited
Systemic Sclerosis
14.6.4.3.2.
Diffused
Systemic Sclerosis
14.6.4.3.3.
Systemic
Sclerosis Sine Scleroderma
14.6.4.4.
New
Zealand Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
14.6.4.4.1.
Oral
14.6.4.4.2.
Parenteral
14.6.5. Australia
14.6.5.1.
Australia
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.6.5.1.1.
Immunosuppressant
14.6.5.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
14.6.5.1.3.
Endothelin
Receptor Antagonists
14.6.5.1.4.
Prostacyclin
Analogues
14.6.5.1.5.
Calcium
Channel Blockers
14.6.5.1.6.
Others
14.6.5.2.
Australia
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.5.2.1.
Offline
14.6.5.2.2.
Online
14.6.5.3.
Australia
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
14.6.5.3.1.
Limited
Systemic Sclerosis
14.6.5.3.2.
Diffused
Systemic Sclerosis
14.6.5.3.3.
Systemic
Sclerosis Sine Scleroderma
14.6.5.4.
Australia
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.6.5.4.1.
Oral
14.6.5.4.2.
Parenteral
14.6.6. South Korea
14.6.6.1.
South
Korea Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Drug Class
14.6.6.1.1.
Immunosuppressant
14.6.6.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
14.6.6.1.3.
Endothelin
Receptor Antagonists
14.6.6.1.4.
Prostacyclin
Analogues
14.6.6.1.5.
Calcium
Channel Blockers
14.6.6.1.6.
Others
14.6.6.2.
South
Korea Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.6.2.1.
Offline
14.6.6.2.2.
Online
14.6.6.3.
South
Korea Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
14.6.6.3.1.
Limited
Systemic Sclerosis
14.6.6.3.2.
Diffused
Systemic Sclerosis
14.6.6.3.3.
Systemic
Sclerosis Sine Scleroderma
14.6.6.4.
South
Korea Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.6.6.4.1.
Oral
14.6.6.4.2.
Parenteral
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.6.7.1.1.
Immunosuppressant
14.6.7.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
14.6.7.1.3.
Endothelin
Receptor Antagonists
14.6.7.1.4.
Prostacyclin
Analogues
14.6.7.1.5.
Calcium
Channel Blockers
14.6.7.1.6.
Others
14.6.7.2.
Southeast
Asia Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.7.2.1.
Offline
14.6.7.2.2.
Online
14.6.7.3.
Southeast
Asia Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
14.6.7.3.1.
Limited
Systemic Sclerosis
14.6.7.3.2.
Diffused
Systemic Sclerosis
14.6.7.3.3.
Systemic
Sclerosis Sine Scleroderma
14.6.7.4.
Southeast
Asia Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.6.7.4.1.
Oral
14.6.7.4.2.
Parenteral
14.6.7.5.
Southeast
Asia Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.6.8.1.1.
Immunosuppressant
14.6.8.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
14.6.8.1.3.
Endothelin
Receptor Antagonists
14.6.8.1.4.
Prostacyclin
Analogues
14.6.8.1.5.
Calcium
Channel Blockers
14.6.8.1.6.
Others
14.6.8.2.
Rest of
Asia Pacific Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.8.2.1.
Offline
14.6.8.2.2.
Online
14.6.8.3.
Rest of
Asia Pacific Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Disease Type
14.6.8.3.1.
Limited
Systemic Sclerosis
14.6.8.3.2.
Diffused
Systemic Sclerosis
14.6.8.3.3.
Systemic
Sclerosis Sine Scleroderma
14.6.8.4.
Rest of
Asia Pacific Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.8.4.1.
Oral
14.6.8.4.2.
Parenteral
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Drug Class
14.7.3. By Distribution Channel
14.7.4. By Disease Type
14.7.5. By Route of Administration
15. Middle East and Africa Systemic Scleroderma
Treatment Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Middle East and Africa Systemic Scleroderma
Treatment Market Revenue (US$ Mn)
15.2. Middle East and Africa Systemic Scleroderma
Treatment Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.2.1. Immunosuppressant
15.2.2. Phosphodiesterase 5 Inhibitors (PHA)
15.2.3. Endothelin Receptor Antagonists
15.2.4. Prostacyclin Analogues
15.2.5. Calcium Channel Blockers
15.2.6. Others
15.3. Middle East and Africa Systemic Scleroderma
Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.3.1. Offline
15.3.2. Online
15.4. Middle East and Africa Systemic Scleroderma
Treatment Market Revenue (US$ Mn) and Forecasts, By Disease Type
15.4.1. Limited Systemic Sclerosis
15.4.2. Diffused Systemic Sclerosis
15.4.3. Systemic Sclerosis Sine Scleroderma
15.5. Middle East and Africa Systemic Scleroderma
Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.5.1. Oral
15.5.2. Parenteral
15.6. Middle East and Africa Systemic Scleroderma
Treatment Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Drug Class
15.6.1.1.1.
Immunosuppressant
15.6.1.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
15.6.1.1.3.
Endothelin
Receptor Antagonists
15.6.1.1.4.
Prostacyclin
Analogues
15.6.1.1.5.
Calcium
Channel Blockers
15.6.1.1.6.
Others
15.6.1.2.
Saudi
Arabia Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.6.1.2.1.
Offline
15.6.1.2.2.
Online
15.6.1.3.
Saudi
Arabia Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
15.6.1.3.1.
Limited
Systemic Sclerosis
15.6.1.3.2.
Diffused
Systemic Sclerosis
15.6.1.3.3.
Systemic
Sclerosis Sine Scleroderma
15.6.1.4.
Saudi
Arabia Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.6.1.4.1.
Oral
15.6.1.4.2.
Parenteral
15.6.2. UAE
15.6.2.1.
UAE
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
15.6.2.1.1.
Immunosuppressant
15.6.2.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
15.6.2.1.3.
Endothelin
Receptor Antagonists
15.6.2.1.4.
Prostacyclin
Analogues
15.6.2.1.5.
Calcium
Channel Blockers
15.6.2.1.6.
Others
15.6.2.2.
UAE
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.6.2.2.1.
Offline
15.6.2.2.2.
Online
15.6.2.3.
UAE
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
15.6.2.3.1.
Limited
Systemic Sclerosis
15.6.2.3.2.
Diffused
Systemic Sclerosis
15.6.2.3.3.
Systemic
Sclerosis Sine Scleroderma
15.6.2.4.
UAE
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.6.2.4.1.
Oral
15.6.2.4.2.
Parenteral
15.6.3. Egypt
15.6.3.1.
Egypt
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
15.6.3.1.1.
Immunosuppressant
15.6.3.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
15.6.3.1.3.
Endothelin
Receptor Antagonists
15.6.3.1.4.
Prostacyclin
Analogues
15.6.3.1.5.
Calcium
Channel Blockers
15.6.3.1.6.
Others
15.6.3.2.
Egypt
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.6.3.2.1.
Offline
15.6.3.2.2.
Online
15.6.3.3.
Egypt
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
15.6.3.3.1.
Limited
Systemic Sclerosis
15.6.3.3.2.
Diffused
Systemic Sclerosis
15.6.3.3.3.
Systemic
Sclerosis Sine Scleroderma
15.6.3.4.
Egypt
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.6.3.4.1.
Oral
15.6.3.4.2.
Parenteral
15.6.4. Kuwait
15.6.4.1.
Kuwait
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
15.6.4.1.1.
Immunosuppressant
15.6.4.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
15.6.4.1.3.
Endothelin
Receptor Antagonists
15.6.4.1.4.
Prostacyclin
Analogues
15.6.4.1.5.
Calcium
Channel Blockers
15.6.4.1.6.
Others
15.6.4.2.
Kuwait
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.6.4.2.1.
Offline
15.6.4.2.2.
Online
15.6.4.3.
Kuwait
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
15.6.4.3.1.
Limited
Systemic Sclerosis
15.6.4.3.2.
Diffused
Systemic Sclerosis
15.6.4.3.3.
Systemic
Sclerosis Sine Scleroderma
15.6.4.4.
Kuwait
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.6.4.4.1.
Oral
15.6.4.4.2.
Parenteral
15.6.5. South Africa
15.6.5.1.
South
Africa Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Drug Class
15.6.5.1.1.
Immunosuppressant
15.6.5.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
15.6.5.1.3.
Endothelin
Receptor Antagonists
15.6.5.1.4.
Prostacyclin
Analogues
15.6.5.1.5.
Calcium
Channel Blockers
15.6.5.1.6.
Others
15.6.5.2.
South
Africa Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.6.5.2.1.
Offline
15.6.5.2.2.
Online
15.6.5.3.
South
Africa Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
15.6.5.3.1.
Limited
Systemic Sclerosis
15.6.5.3.2.
Diffused
Systemic Sclerosis
15.6.5.3.3.
Systemic
Sclerosis Sine Scleroderma
15.6.5.4.
South Africa
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.6.5.4.1.
Oral
15.6.5.4.2.
Parenteral
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Systemic Scleroderma Treatment Market Revenue (US$ Mn)
and Forecasts, By Drug Class
15.6.6.1.1.
Immunosuppressant
15.6.6.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
15.6.6.1.3.
Endothelin
Receptor Antagonists
15.6.6.1.4.
Prostacyclin
Analogues
15.6.6.1.5.
Calcium
Channel Blockers
15.6.6.1.6.
Others
15.6.6.2.
Rest of
Middle East & Africa Systemic Scleroderma Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
15.6.6.2.1.
Offline
15.6.6.2.2.
Online
15.6.6.3.
Rest of
Middle East & Africa Systemic Scleroderma Treatment Market Revenue (US$ Mn)
and Forecasts, By Disease Type
15.6.6.3.1.
Limited
Systemic Sclerosis
15.6.6.3.2.
Diffused
Systemic Sclerosis
15.6.6.3.3.
Systemic
Sclerosis Sine Scleroderma
15.6.6.4.
Rest of
Middle East & Africa Systemic Scleroderma Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.6.6.4.1.
Oral
15.6.6.4.2.
Parenteral
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Drug Class
15.7.3. By Distribution Channel
15.7.4. By Disease Type
15.7.5. By Route of Administration
16. Latin America Systemic Scleroderma Treatment
Market Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Latin America Systemic Scleroderma Treatment
Market Revenue (US$ Mn)
16.2. Latin America Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.2.1. Immunosuppressant
16.2.2. Phosphodiesterase 5 Inhibitors (PHA)
16.2.3. Endothelin Receptor Antagonists
16.2.4. Prostacyclin Analogues
16.2.5. Calcium Channel Blockers
16.2.6. Others
16.3. Latin America Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.3.1. Offline
16.3.2. Online
16.4. Latin America Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Disease Type
16.4.1. Limited Systemic Sclerosis
16.4.2. Diffused Systemic Sclerosis
16.4.3. Systemic Sclerosis Sine Scleroderma
16.5. Latin America Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.5.1. Oral
16.5.2. Parenteral
16.6. Latin America Systemic Scleroderma Treatment
Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
16.6.1.1.1.
Immunosuppressant
16.6.1.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
16.6.1.1.3.
Endothelin
Receptor Antagonists
16.6.1.1.4.
Prostacyclin
Analogues
16.6.1.1.5.
Calcium
Channel Blockers
16.6.1.1.6.
Others
16.6.1.2.
Brazil
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.6.1.2.1.
Offline
16.6.1.2.2.
Online
16.6.1.3.
Brazil
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
16.6.1.3.1.
Limited
Systemic Sclerosis
16.6.1.3.2.
Diffused
Systemic Sclerosis
16.6.1.3.3.
Systemic
Sclerosis Sine Scleroderma
16.6.1.4.
Brazil
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.6.1.4.1.
Oral
16.6.1.4.2.
Parenteral
16.6.2. Argentina
16.6.2.1.
Argentina
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Drug
Class
16.6.2.1.1.
Immunosuppressant
16.6.2.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
16.6.2.1.3.
Endothelin
Receptor Antagonists
16.6.2.1.4.
Prostacyclin
Analogues
16.6.2.1.5.
Calcium
Channel Blockers
16.6.2.1.6.
Others
16.6.2.2.
Argentina
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.6.2.2.1.
Offline
16.6.2.2.2.
Online
16.6.2.3.
Argentina
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By
Disease Type
16.6.2.3.1.
Limited
Systemic Sclerosis
16.6.2.3.2.
Diffused
Systemic Sclerosis
16.6.2.3.3.
Systemic
Sclerosis Sine Scleroderma
16.6.2.4.
Argentina
Systemic Scleroderma Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.6.2.4.1.
Oral
16.6.2.4.2.
Parenteral
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Drug Class
16.6.3.1.1.
Immunosuppressant
16.6.3.1.2.
Phosphodiesterase
5 Inhibitors (PHA)
16.6.3.1.3.
Endothelin
Receptor Antagonists
16.6.3.1.4.
Prostacyclin
Analogues
16.6.3.1.5.
Calcium
Channel Blockers
16.6.3.1.6.
Others
16.6.3.2.
Rest of
Latin America Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.6.3.2.1.
Offline
16.6.3.2.2.
Online
16.6.3.3.
Rest of
Latin America Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Disease Type
16.6.3.3.1.
Limited
Systemic Sclerosis
16.6.3.3.2.
Diffused
Systemic Sclerosis
16.6.3.3.3.
Systemic
Sclerosis Sine Scleroderma
16.6.3.4.
Rest of
Latin America Systemic Scleroderma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.6.3.4.1.
Oral
16.6.3.4.2.
Parenteral
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Drug Class
16.7.3. By Distribution Channel
16.7.4. By Disease Type
16.7.5. By Route of Administration
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2021
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. Amgen Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Argentis Pharmaceuticals, LLC
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Bayer AG
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Biogen
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Boehringer Ingelheim International GmbH
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Bristol-Myers Squibb Company
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Celgene Corporation
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Corbus Pharmaceuticals Holdings, Inc
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Eli Lilly and Company
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. GlaxoSmithKline plc
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Hoffmann La Roche Ltd.
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Johnson & Johnson Services, Inc.
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Mylan N.V.
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Novartis AG
18.14.1. Company Details
18.14.2. Company Overview
18.14.3. Product Offerings
18.14.4. Key Developments
18.14.5. Financial Analysis
18.14.6. SWOT Analysis
18.14.7. Business Strategies
18.15. Ono pharmaceutical co. Ltd.
18.15.1. Company Details
18.15.2. Company Overview
18.15.3. Product Offerings
18.15.4. Key Developments
18.15.5. Financial Analysis
18.15.6. SWOT Analysis
18.15.7. Business Strategies
18.16. Pfizer Inc.
18.16.1. Company Details
18.16.2. Company Overview
18.16.3. Product Offerings
18.16.4. Key Developments
18.16.5. Financial Analysis
18.16.6. SWOT Analysis
18.16.7. Business Strategies
18.17. Sanofi
18.17.1. Company Details
18.17.2. Company Overview
18.17.3. Product Offerings
18.17.4. Key Developments
18.17.5. Financial Analysis
18.17.6. SWOT Analysis
18.17.7. Business Strategies
18.18. Teva Pharmaceutical Industries Ltd.
18.18.1. Company Details
18.18.2. Company Overview
18.18.3. Product Offerings
18.18.4. Key Developments
18.18.5. Financial Analysis
18.18.6. SWOT Analysis
18.18.7. Business Strategies
18.19. United Therapeutics
18.19.1. Company Details
18.19.2. Company Overview
18.19.3. Product Offerings
18.19.4. Key Developments
18.19.5. Financial Analysis
18.19.6. SWOT Analysis
18.19.7. Business Strategies
18.20. Other Market Participants
19. Key Findings
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
